American Bio Medica Corp ABMC Stock Analysis
- PINK
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.00 unchanged at close Nov 5
Last close · Previous close $0.00
- Market cap
- At the Nov 5 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$0.01Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$0.00unchangedThu, Nov 5 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.00Nov 4
- Volume0.00Nov 5 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume0.00Last 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.00 to $0.00; now $0.00
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 5 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
ABMC beat the S&P 500 in 2 of 5 periods.
| Period | ABMC and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ABMC: unchanged S&P 500: down 5.4% | ABMC beat the S&P 500 by 5.4 percentage points Beat |
| 3M | ABMC: unchanged S&P 500: down 4.5% | ABMC beat the S&P 500 by 4.5 percentage points Beat |
| Long term | ||
| 3Y | ABMC: down 99.8% S&P 500: up 74.8% −88.1% vs +20.5% a year | ABMC trailed the S&P 500 by 174.6 percentage points Trailed |
| 5Y | ABMC: down 100.0% S&P 500: up 67.3% −88.6% vs +10.8% a year | ABMC trailed the S&P 500 by 167.3 percentage points Trailed |
| 10Y | ABMC: down 100.0% S&P 500: up 311.8% −69.0% vs +15.2% a year | ABMC trailed the S&P 500 by 411.8 percentage points Trailed |
$10,000 invested in ABMC 10 years ago (Nov 4, 2016) would be worth about $0 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,184.
ABMC beat the S&P 500 in 2 of 5 periods.
| Period | ABMC and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ABMC: unchanged S&P 500: down 5.4% | ABMC beat the S&P 500 by 5.4 percentage points Beat |
| 3M | ABMC: unchanged S&P 500: down 4.8% | ABMC beat the S&P 500 by 4.8 percentage points Beat |
| Long term | ||
| 3Y | ABMC: down 99.8% S&P 500: up 68.6% −88.1% vs +19.0% a year | ABMC trailed the S&P 500 by 168.4 percentage points Trailed |
| 5Y | ABMC: down 100.0% S&P 500: up 56.4% −88.6% vs +9.4% a year | ABMC trailed the S&P 500 by 156.4 percentage points Trailed |
| 10Y | ABMC: down 100.0% S&P 500: up 251.5% −69.0% vs +13.4% a year | ABMC trailed the S&P 500 by 351.5 percentage points Trailed |
$10,000 invested in ABMC 10 years ago (Nov 4, 2016) would be worth about $0 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,147.
All-time high
$6.50
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Feb 14, 1997.
Stock splits
ABMC hasn’t split since its price history begins in 1997.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY22, the quarter ended Jun 30, 2022. “Last 12 months” means the four quarters from Jul 1, 2021 to Jun 30, 2022, and balance-sheet figures are as of Jun 30, 2022.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $1.66M
- Net income
- −$441.00K
- Diluted EPS
- −$0.01
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY20 (Dec 31, 2020) | $777.00K | −$233.00K | $0.00 |
| Q1 FY21 (Mar 31, 2021) | $566.00K | −$556.00K | −$0.01 |
| Q2 FY21 (Jun 30, 2021) | $529.00K | −$245.00K | −$0.01 |
| Q3 FY21 (Sep 30, 2021) | $614.00K | $663.00K | $0.02 |
| Q4 FY21 (Dec 31, 2021) | $509.00K | −$325.00K | −$0.01 |
| Q1 FY22 (Mar 31, 2022) | $351.00K | −$379.00K | −$0.01 |
| Q2 FY22 (Jun 30, 2022) | $185.00K | −$400.00K | −$0.01 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY20 (Dec 31, 2020) | $4.15M | −$796.00K | −$0.02 |
| FY21 (Dec 31, 2021) | $2.22M | −$463.00K | −$0.01 |
Margins
- Gross 15.8%
- Operating −66.5%
- Net −26.6%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$139.00KLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$139.00KLast 12 months
- Capital spending$0.00Last 12 months
- −8.4%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $100.00KLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $2.00KAs of Jun 30, 2022
Cash plus short- and long-term marketable securities on the Jun 30, 2022 balance sheet.
- Total debt$1.53MAs of Jun 30, 2022
- Net debt$1.53MAs of Jun 30, 2022
- 0.25As of Jun 30, 2022
Current assets divided by current liabilities on the Jun 30, 2022 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
- −25.3%Last 12 months
Over the last 12 months, American Bio Medica’s net loss was 25.3% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About American Bio Medica Corp
American Bio Medica Corporation develops, manufactures and sells immunoassay tests for the immediate, point of collection testing (POCT) for drugs of abuse (DOA) in urine and oral fluids. The Company's DOA testing products offer employers, law enforcement, government, health care, laboratory and education professionals, self-contained products capable of identifying illicit drug use within minutes. In addition to the manufacture and sale of DOA testing products, it provides bulk test strip contract manufacturing services for other POCT companies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- New York, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- PINK
- Asset type
- Common stock
- Price history since
ABMC news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
ABMC stock FAQ
What is ABMC stock’s price today?
American Bio Medica (ABMC) traded at $0.00 at the close on , unchanged from the previous close of $0.00. Over the past 52 weeks it has traded between $0.00 and $0.00.
If you invested $1,000 in ABMC 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in ABMC on would be worth about $0 at the close on , a total return of −100.0%. The same $1,000 would be worth $0 if invested five years ago and $0 if invested 20 years ago. Past performance doesn’t predict future returns.
What is ABMC’s P/E ratio?
ABMC’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$0.01).
How much revenue does American Bio Medica make?
American Bio Medica reported $1.7 million of revenue over the four quarters to . In its latest quarter (Q2 FY22, ended ) revenue was $185.0 thousand, down 65.0% from a year earlier.
Is American Bio Medica profitable?
Not over the four quarters to . American Bio Medica reported a net loss of $441.0 thousand across those four quarters on $1.7 million of revenue.
What are ABMC’s earnings per share?
ABMC’s diluted earnings per share were −$0.01 over the four quarters to . The latest quarter (Q2 FY22) brought −$0.01 per share, against −$0.01 a year earlier (how EPS works).
Does ABMC pay a dividend?
American Bio Medica hasn’t paid a dividend in the last twelve months.
What is ABMC’s 52-week high and low?
Over the past 52 weeks ABMC has traded as low as $0.00 and as high as $0.00. At $0.00 at the close on , it is 0.0% below that high and 0.0% above the low.
What is ABMC’s all-time high?
ABMC’s highest closing price was $6.50 on , adjusted for stock splits. At $0.00 at the close on , it is 100.0% below that record.
Has ABMC stock ever split?
No. ABMC hasn’t split since its price history begins in 1997.
What sector and industry is American Bio Medica in?
American Bio Medica is in the Healthcare sector and the Biotechnology industry, and is headquartered in New York, USA.
What exchange does ABMC trade on?
American Bio Medica trades on the PINK under the ticker symbol ABMC. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.